Next report date
Report period
Q1 2024
EPS estimate
−0.18USD
Revenue estimate
8.50 MUSD
−171.67 MUSD
36.86 MUSD
91.97 M
Om Mersana Therapeutics, Inc.
Sektor
Bransch
VD
Martin H. Huber
Webbplats
Huvudkvarter
Cambridge
Employees (FY)
123
Grundat
2001
FIGI
BBG001CPSVF3
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
